Skip to content
DataLookout
Menu

SEMAFOLLOWNCT07423481

Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 1, 2026 to Oct 21, 2026
    • Primary and study completion dates: Jul 1, 2027 to Jul 21, 2027
    • Site details revised
  2. Notable Start date: Jun 1, 2026 to Oct 1, 2026
    • Eligibility criteria expanded, about 3 words
    • Primary and study completion pushed from Mar 1, 2027 to Jul 1, 2027
    • Collaborators: details revised at 1 of 1 entry
  3. Minor Secondary endpoints: details revised at 3 of 3 entriesv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Describe weight changes during the follow-up period according to patient characteristics.
Timeframe: Baseline

Secondary (3)

Identify the characteristics of patients who continue treatment or switch to other obesity management strategies and the associated factors.
Compare the profiles of responders and non-responders
Describe weight change according to different subpopulations.

Arms and interventions

SEMAFOLLOW study population

Patient agreeing to participate in the SEMAFOLLOW study.

Other: SEMAFOLLOW questionnaire

Sites

1 site in 1 country

  • Nantes university hospitalNantes, France